Gold L S, Slone T H, Stern B R, Bernstein L
Life Sciences Division, Lawrence Berkeley Laboratory, Berkeley, CA 94720.
Mutat Res. 1993 Mar;286(1):75-100. doi: 10.1016/0027-5107(93)90004-y.
A comparison of target organs for mutagens and non-mutagens is presented for 351 rodent carcinogens in the Carcinogenic Potency Database (CPDB) with mutagenicity evaluations in Salmonella. Results are consistent with the hypotheses that in high-dose rodent tests mitogenesis is important in the carcinogenic response for mutagens and non-mutagens alike, and that mutagens have a multiplicative interaction for carcinogenicity because they can both damage DNA directly and cause cell division at high doses. These hypotheses would lead one to expect several results that are found in the analysis: First, a high proportion of both mutagens and non-mutagens induce tumors in rodent bioassays at the MTD. Second, mutagens compared to non-mutagens are: (a) more likely to be carcinogenic; (b) more likely to induce tumors at multiple target sites; and (c) more likely to be carcinogenic in two species. Among carcinogens that induce tumors at multiple sites in both rats and mice, 81% are mutagens; in comparison, among carcinogens that are positive at only a single target site in one species and are negative in the other, 42% are mutagens. Since tissue distribution and pharmacokinetics would not be expected to differ systematically between mutagens and non-mutagens, one would not expect systematic differences in the particular organs in which tumors are induced. Results do not support the idea that mutagens and non-mutagens induce tumors in different target organs. Both mutagens and non-mutagens induce tumors in a wide variety of sites, and most organs are target sites for both. Moreover, the same sites tend to be the most common sites for both: 79% or more of both mutagenic and non-mutagenic carcinogens are positive in each species in at least one of the 8 most frequent target sites: liver, lung, mammary gland, stomach, vascular system, kidney, hematopoietic system and urinary bladder. Species differences are discussed as well as results for particular target organs: liver, Zymbal's gland and kidney.
在致癌潜能数据库(CPDB)中,对351种啮齿动物致癌物的诱变剂和非诱变剂的靶器官进行了比较,并在沙门氏菌中进行了致突变性评估。结果与以下假设一致:在高剂量啮齿动物试验中,有丝分裂在诱变剂和非诱变剂的致癌反应中都很重要;诱变剂在致癌性方面具有倍增相互作用,因为它们既能直接损伤DNA,又能在高剂量下导致细胞分裂。这些假设会让人预期在分析中会发现几个结果:第一,诱变剂和非诱变剂在啮齿动物生物测定中,在最大耐受剂量(MTD)时都有很高比例会诱发肿瘤。第二,与非诱变剂相比,诱变剂:(a)更有可能具有致癌性;(b)更有可能在多个靶器官诱发肿瘤;(c)更有可能在两个物种中都具有致癌性。在大鼠和小鼠中都能在多个部位诱发肿瘤的致癌物中,81%是诱变剂;相比之下,在仅在一个物种的单个靶器官呈阳性而在另一个物种呈阴性的致癌物中,42%是诱变剂。由于预计诱变剂和非诱变剂之间的组织分布和药代动力学不会有系统性差异,因此不会预期在诱发肿瘤的特定器官中有系统性差异。结果不支持诱变剂和非诱变剂在不同靶器官诱发肿瘤的观点。诱变剂和非诱变剂都能在广泛的部位诱发肿瘤,大多数器官都是两者的靶器官。此外,相同的部位往往是两者最常见的部位:在8个最常见的靶器官(肝脏、肺、乳腺、胃、血管系统、肾脏、造血系统和膀胱)中,至少有一个器官中,79%或更多的诱变剂和非诱变剂致癌物在每个物种中呈阳性。文中还讨论了物种差异以及特定靶器官(肝脏、齐默尔氏腺和肾脏)的结果。